ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eton Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$49.22−1.09 (-2.17%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Eton Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.41B | $197.05M |
| Enterprise Value | $1.41B | $106.56M |
| PE Ratio | 126.20 | 20.52 |
| PS Ratio | 13.32 | 3.93 |
| PB Ratio | 30.20 | 2.14 |
| P/TBV Ratio | 1551.12 | 2.46 |
| P/FCF Ratio | 95.50 | 18.25 |
| P/OCF Ratio | 92.95 | 13.78 |
Enterprise value
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 13.33 | 2.69 |
| EV / EBITDA | 67.52 | 14.86 |
| EV / EBIT | 86.33 | 19.00 |
| EV / FCF | 95.57 | 21.02 |
Income (trailing twelve months)
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $105.60M | $57.94M |
| Gross Profit | $61.10M | $90.47M |
| Operating Income | $16.31M | -$21.44M |
| Pretax Income | $12.75M | -$14.45M |
| Net Income | $12.69M | -$22.46M |
| EBITDA | $20.85M | -$16.91M |
| EPS (Diluted) | $0.39 | -$0.83 |
Margins
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 57.9% | 52.3% |
| Operating Margin | 15.4% | -44.5% |
| Pretax Margin | 12.1% | -13.0% |
| Profit Margin | 12.0% | -39.2% |
| EBITDA Margin | 19.7% | -31.3% |
| FCF Margin | 14.0% | -8.85% |
Returns
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 36.0% | -53.1% |
| Return on Assets (ROA) | 11.7% | -41.0% |
| Return on Invested Capital (ROIC) | 42.5% | -32.0% |
| Return on Capital Employed (ROCE) | 23.1% | -37.8% |
Growth
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 81.5% | 6.01% |
| FCF Growth (YoY) | 20.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 55.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 359.6% | 6.42% |
Balance sheet
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $26.85M | $62.42M |
| Total Debt | $27.90M | $120.13M |
| Net Cash (Debt) | -$1.06M | $15.68M |
| Net Cash Per Share | -$0.04 | $0.65 |
| Equity (Book Value) | $46.59M | $48.79M |
| Book Value Per Share | $1.63 | $1.36 |
| Tangible Book Value | $907.00K | $23.06M |
| Working Capital | $23.48M | $75.77M |
Financial position
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.52 | 3.30 |
| Quick Ratio | 1.15 | 2.39 |
| Debt / Equity | 0.60 | 0.51 |
| Debt / EBITDA | 1.34 | 3.35 |
| Debt / FCF | 1.89 | 5.05 |
| Net Debt / EBITDA | 0.05 | 2.22 |
| Interest Coverage | 3.57 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $15.14M | -$12.35M |
| Capital Expenditures | -$403.00K | -$1.06M |
| Free Cash Flow | $14.73M | -$20.28M |
| FCF Per Share | $0.52 | -$0.41 |
Efficiency
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.97 | 0.38 |
| Inventory Turnover | 2.62 | 2.67 |
| Revenue Per Employee | $2.40M | $398.96K |
| Profits Per Employee | $288.36K | -$732.08K |
| Employee Count | 44 | 73 |
Dividends and yields
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 0.90% | -21.2% |
| FCF Yield | 1.05% | -7.64% |
Shares
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 28,583,100 | 59,128,900 |
| Shares Change (YoY) | 11.0% | 11.1% |
| Shares Change (QoQ) | 3.40% | 0.54% |
| Float | 24,226,500 | 48,744,500 |
| Shares Held by Insiders | 15.2% | 11.8% |
| Shares Held by Institutions | 74.0% | 59.4% |
Taxes
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $63.00K | $91.50K |
| Effective Tax Rate | 0.49% | 20.6% |
Scores
| Measure | Eton Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $3.78 | $17.36 |
| Graham Upside | -92.3% | -45.5% |
| Altman Z-Score | 12.61 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Eton Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.